RDJ advises Agilent Technologies on its acquisition of Luxcel Biosciences Limited

RDJ advised Agilent Technologies (NYSE: A) on its acquisition of Cork-based Luxcel Biosciences Limited. The acquisition expands Agilent's cell analysis portfolio with the addition of easy-to-use assay kits that are compatible with industry standard plate-readers.

Headquartered in California, Agilent Technologies is a global leader in life sciences, diagnostics and applied chemical markets. The company generated revenues of $4.47 billion in fiscal 2017 and employs 13,500 people worldwide.

Founded as a spin-out company from University College Cork, Luxcel is a provider of cost effective and easy-to-use fluorescence-based in vitro cell test kits, targeting cell metabolism, bioenergetics and drug toxicity applications.

Cork-based corporate partner Diarmaid Gavin led the RDJ deal team assisted by solicitor Sarah Slevin. Advices on employment and tax aspects were provided by partner Deirdre Malone and associate Mark Ludlow respectively.